Comparative Pharmacology
Head-to-head clinical analysis: APRETUDE versus TIVICAY PD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APRETUDE versus TIVICAY PD.
APRETUDE vs TIVICAY PD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Apretude (cabotegravir) is an HIV-1 integrase strand transfer inhibitor (INSTI) that inhibits the integration of HIV-1 DNA into host genomic DNA, which is essential for viral replication. It binds to the active site of integrase and blocks the strand transfer step of retroviral DNA integration.
Tivicay PD (dolutegravir) is an HIV-1 integrase strand transfer inhibitor (INSTI) that inhibits the catalytic activity of HIV-1 integrase, preventing the integration of viral DNA into host chromosomal DNA, which is essential for viral replication.
600 mg IM every 2 months, initiated as two consecutive monthly loading doses of 600 mg each, for HIV-1 pre-exposure prophylaxis.
50 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 40 hours following subcutaneous injection, supporting monthly dosing.
Terminal elimination half-life is approximately 12-15 hours in adults, supporting once-daily dosing.
Renal (approximately 30% as unchanged drug) and fecal (approximately 50% as metabolites and unchanged drug) following oral administration.
Primarily metabolized by UGT1A1 with minor CYP3A4; 53% of dose recovered in feces (30% as unchanged drug) and 31% in urine (18% as unchanged drug).
Category C
Category C
Antiretroviral
Antiretroviral, integrase inhibitor